Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Potential Targeting Ph + Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity

Justine Yu, B.S., Giovannino Silvestri, PhD, Lorenzo Stramucci, PhD, Masashi Sanada, MD PhD, Tomoyuki Yamaguchi, PhD, Yang Du, PhD, Jukka Westermarck, MD PhD, Michael A. Caligiuri, MD, Ramiro Garzon, MD, Dragana Milojkovic, MD, Jane F. Apperley, MD, Denis-Claude Roy, MD, Guido Marcucci, MD, Bruno Calabretta, MD PhD, Maria R. Baer, MD, Rossana Trotta, PhD, Danilo Perrotti, MD PhD

Blood (2016) 128 (22): 2909.

https://doi.org/10.1182/blood.V128.22.2909.2909

Published: 2016

Journal Articles

The Intensive Care Trial for Critically Ill Onco-Haematologic Patients: The Need for Response Criteria at 5 Days of Full Treatment to Separate Good Risk Patients and Avoid Futile Intensive Care Interventions

Blood (2016) 128 (22): 5987.

https://doi.org/10.1182/blood.V128.22.5987.5987

Published: 2016

Journal Articles

Elevated Preconditioning Serum Levels of C-Reactive Protein Are Associated with Increased Nonrelapse Mortality and Inferior Survival After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation

Jiri Pavlu, Katayoun Rezvani, Bhuvan Kishore, Rifca Le Dieu, Joydeep Chakrabartty, Aristeidis Chaidos, Edward J Kanfer, Anastasios Karadimitris, Donald H MacDonald, David Marin, Dragana Milojkovic, MD, Farah O'Boyle, Amin Rahemtulla, David Slade, John M Goldman, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Richard M Szydlo

Blood (2011) 118 (21): 1945.

https://doi.org/10.1182/blood.V118.21.1945.1945

Published: 2011

Journal Articles

Prolonged Survival Following Imatinib Failure for CML Patients in CP May Require Multiple TKI Strategies for Responding Patients,

Dragana Milojkovic, MD, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Amr R Ibrahim, Marco Bua, MD, Alistair Reid, PhD, Gareth Gerrard, PhD, Letizia Foroni, MD PhD, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, David Marin

Blood (2011) 118 (21): 3777.

https://doi.org/10.1182/blood.V118.21.3777.3777

Published: 2011

Journal Articles

Cryopreserved Allogeneic Peripheral Blood Stem Cells Result in Outcome Equivalent to Those of Fresh Infusions Enabling Rational Scheduling of Donations,

Bhuvan Kishore, John Davis, Katayoun Rezvani, MD, PhD, David Marin, Richard M Szydlo, Loaiza Sandra, Giles Chrissy, Aristeidis Chaidos, Edward J Kanfer, Anastasios Karadimitris, Donald H MacDonald, Dragana Milojkovic, MD, Amin Rahemtulla, John M Goldman, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Jiri Pavlu

Blood (2011) 118 (21): 4052.

https://doi.org/10.1182/blood.V118.21.4052.4052

Published: 2011

Journal Articles

Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets,

Blood (2011) 118 (21): 3753.

https://doi.org/10.1182/blood.V118.21.3753.3753

Published: 2011

Journal Articles

The Majority of Patients Receiving Donor Lymphocyte Infusions for Relapsed Chronic Myeloid Leukemia Remain PCR Positive Despite Maintaining Long-Term Remission,

Andrew J Innes, MBChB, James Lurkins, Richard M Szydlo, Andrea Guerra, Dragana Milojkovic, MD, Jiri Pavlu, Edward J Kanfer, David Marin, Donald MacDonald, Amin Rahemtulla, Sandra Loaiza, Stephanie Kirschke, Katayoun Rezvani, MD, PhD, John Goldman, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Francesco Dazzi

Blood (2011) 118 (21): 4103.

https://doi.org/10.1182/blood.V118.21.4103.4103

Published: 2011

Journal Articles

The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies

Dragana Milojkovic, MD, Gareth Gerrard, PhD, Christos Paliompeis, Marco Bua, MD, Alistair Reid, PhD, Mary Alikian, Jamshid Khorashad, MD, PhD, John M Goldman, David Marin, Letizia Foroni, MD PhD, Jane F Apperley, MBChB, MD, FRCP, FRCPath

Blood (2011) 118 (21): 605.

https://doi.org/10.1182/blood.V118.21.605.605

Published: 2011

Journal Articles

The Predictive Value of Early Molecular Response in Chronic Phase CML Patients Treated with Dasatinib First Line Therapy

David Marin, Corinne Hedgley, Richard E Clark, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Letizia Foroni, MD PhD, Dragana Milojkovic, MD, Christopher Pocock, John M Goldman, Stephen O'Brien

Blood (2011) 118 (21): 785.

https://doi.org/10.1182/blood.V118.21.785.785

Published: 2011

Journal Articles

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

Dragana Milojkovic, MD, Amr R Ibrahim, Letizia Foroni, MD PhD, Claire Lucas, Gareth Gerrard, PhD, Lihui Wang, Richard M Szydlo, Richard E Clark, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Marco Bua, MD, Jiri Pavlu, Christos Paliompeis, Alistair Reid, PhD, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, David Marin

Blood (2011) 118 (21): 1680.

https://doi.org/10.1182/blood.V118.21.1680.1680

Published: 2011

Journal Articles

Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chronic Myeloid Leukemia

Ailsa Holroyd, MD, Elizabeth Phillips, MD, Richard Szydlo, PhD, David Marin, MD, PhD, Letizia Foroni, MD, PhD, Jamshid Khorashad, MD, PhD, Dragana Milojkovic, MD, PhD, Edward J. Kanfer, MD, Francesco Dazzi, Donald H. MacDonald, MD, PhD, Amin Rahemtulla, MBBS, PhD, FRCP, Donal McLornan, MD, PhD, Ian H Gabriel, MD, Jiri Pavlu, MD, Jeremy Sargent, MD, John M. Goldman, MD, PhD, Jane F. Apperley, MD, Katayoun Rezvani, MD, PhD

Blood (2010) 116 (21): 3515.

https://doi.org/10.1182/blood.V116.21.3515.3515

Published: 2010

Journal Articles

KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib

Ian H Gabriel, MD, David Marin, MD, FRCP, Shahzad Ahmad, Mr, Letizia Foroni, Hugues de Lavallade, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Stephen O'Brien, PhD, Ruhena Sergeant, Dragana Milojkovic, MD, Marco Bua, Abdullah Alsuliman, Ahmad Khoder, Dr, Kate Stringaris, MD, MRCP, FRCPath, Nichola Cooper, MD, John M. Goldman, DM, FRCP, FRCPath, FMedSci, Jane F. Apperley, Katayoun Rezvani, MD, PhD

Blood (2010) 116 (21): 888.

https://doi.org/10.1182/blood.V116.21.888.888

Published: 2010

Journal Articles

T-Cell and B-Cell Responses After Vaccination against Influenza Virus and Pneumococcus in Chronic Phase CML Patients Treated with Tyrosine Kinase Inhibitors.

Hugues de Lavallade, MD, MsC, Melanie Hart, PhD, Ian H Gabriel, Dr, Peter Kelleher, MD, PhD, Abdullah Alsuliman, PhD, Ahmad Khoder, MD, Dragana Milojkovic, MD, Letizia Foroni, Marco Bua, MD, Jane F. Apperley, MBChB, FRCP, FRCPath, John M Goldman, DM, FCRP, David Marin, MD, Katayoun Rezvani, MD, PhD

Blood (2009) 114 (22): 2214.

https://doi.org/10.1182/blood.V114.22.2214.2214

Published: 2009

Journal Articles

BCR-ABL1 Oncogene Down-regulates the Expression of OCT1 in CML.

Alexandra Bazeos, David Marin, Gareth Gerrard, PhD, Richard Szydlo, Dragana Milojkovic, MD, Alistair Reid, Hugues de Lavallade, Jane F. Apperley, MBChB, FRCP, FRCPath, John M Goldman, DM, FCRP, FRCPath, Letizia Foroni, Jamshid Sorouri Khorashad, MD

Blood (2009) 114 (22): 3248.

https://doi.org/10.1182/blood.V114.22.3248.3248

Published: 2009

Journal Articles

Outcome, Prognostic Factors and Long-Term Follow-Up in 207 Chronic Phase CML Patients Receiving Front-Line Imatinib 400 mg at a Single Institution.

Hugues de Lavallade, MD, Dragana Milojkovic, MD, Jamshid S. Khorashad, MD, Alistair Reid, PhD, Eduardo Olavarria, MD, Jaspal Kaeda, PhD, John M. Goldman, DM, Jane F. Apperley, MD, David Marin, MD

Blood (2007) 110 (11): 1045.

https://doi.org/10.1182/blood.V110.11.1045.1045

Published: 2007

Journal Articles

Pleural Effusions Associated with Use of Dasatinib in Chronic Myeloid Leukemia May Have an Auto-Immune Pathogenesis.

Sinthiya Punnialingam, Hugues de Lavallade, MD, Dragana Milojkovic, MD, Bua Marco, MD, Jamshid S. Khorashad, MD, John M. Goldman, DM, Jane F. Apperley, MD, David Marin, MD

Blood (2007) 110 (11): 2945.

https://doi.org/10.1182/blood.V110.11.2945.2945

Published: 2007

Journal Articles

For CML Patients in Chronic Phase Who Achieve a Cytogenetic Response to Imatinib the Finding of a BCR-ABL Mutation Predicts for Progression to Advanced Phase but It Has No Such Significance in Primary Resistance.

Hugues de Lavallade, MD, Jamshid S. Khorashad, MD, Dragana Milojkovic, MD, Simon Wagner, PhD, Jaspal Kaeda, PhD, John M. Goldman, DM, Jane F. Apperley, MD, David Marin, MD

Blood (2007) 110 (11): 323.

https://doi.org/10.1182/blood.V110.11.323.323

Published: 2007

Journal Articles

Long Term Durability of Major Molecular Responses for Patients Treated with Imatinib after Failure of Interferon-Alfa Is Equivalent to That of Patients Achieving Major Molecular Responses to Imatinib as Primary Therapy.

Hugues de Lavallade, MD, Jamshid S. Khorashad, MD, Marco Bua, MD, Dragana Milojkovic, MD, Eduardo Olavarria, MD, Alistair Reid, PhD, Jaspal S. Kaeda, PhD, John M. Goldman, DM, Jane F. Apperley, MD, David Marin, MD

Blood (2007) 110 (11): 1037.

https://doi.org/10.1182/blood.V110.11.1037.1037

Published: 2007

Journal Articles

Abnormally Small BCR-ABL Transcripts in CML Patients before and during Imatinib Treatment.

Jamshid S. Khorashad, MD, Jeffrey H. Lipton, MD, David Marin, MD, Dragana Milojkovic, MD, Nicholas C.P. Cross, PhD, Nicholas Dibb, PhD, Junia V. Melo, PhD, Suzanne Kamel-Reid, PhD, John M. Goldman, MD, Jane F. Apperley, PhD, Jaspal S. Kaeda, PhD

Blood (2006) 108 (11): 2153.

https://doi.org/10.1182/blood.V108.11.2153.2153

Published: 2006

Journal Articles

Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd-Chiari Syndrome.

Raj K. Patel, MD, Nicholas Lea, PhD, Michael A. Heneghan, MD, Nigel Westwood, PhD, Dragana Milojkovic, MD, Kumar Thanigaikumar, MD, Deborah Yallop, MD, Roopen Arya, PhD, Antonio Pagliuca, MD, Joop Gaken, PhD, Nigel A. Heaton, MD, Ghulam J. Mufti, MD

Blood (2005) 106 (11): 2588.

https://doi.org/10.1182/blood.V106.11.2588.2588

Published: 2005

NARROW

Potential Targeting Ph + Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity

The Intensive Care Trial for Critically Ill Onco-Haematologic Patients: The Need for Response Criteria at 5 Days of Full Treatment to Separate Good Risk Patients and Avoid Futile Intensive Care Interventions

Elevated Preconditioning Serum Levels of C-Reactive Protein Are Associated with Increased Nonrelapse Mortality and Inferior Survival After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation

Prolonged Survival Following Imatinib Failure for CML Patients in CP May Require Multiple TKI Strategies for Responding Patients,

Cryopreserved Allogeneic Peripheral Blood Stem Cells Result in Outcome Equivalent to Those of Fresh Infusions Enabling Rational Scheduling of Donations,

Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets,

The Majority of Patients Receiving Donor Lymphocyte Infusions for Relapsed Chronic Myeloid Leukemia Remain PCR Positive Despite Maintaining Long-Term Remission,

The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies

The Predictive Value of Early Molecular Response in Chronic Phase CML Patients Treated with Dasatinib First Line Therapy

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chronic Myeloid Leukemia

KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib

T-Cell and B-Cell Responses After Vaccination against Influenza Virus and Pneumococcus in Chronic Phase CML Patients Treated with Tyrosine Kinase Inhibitors.

BCR-ABL1 Oncogene Down-regulates the Expression of OCT1 in CML.

Outcome, Prognostic Factors and Long-Term Follow-Up in 207 Chronic Phase CML Patients Receiving Front-Line Imatinib 400 mg at a Single Institution.

Pleural Effusions Associated with Use of Dasatinib in Chronic Myeloid Leukemia May Have an Auto-Immune Pathogenesis.

For CML Patients in Chronic Phase Who Achieve a Cytogenetic Response to Imatinib the Finding of a BCR-ABL Mutation Predicts for Progression to Advanced Phase but It Has No Such Significance in Primary Resistance.

Long Term Durability of Major Molecular Responses for Patients Treated with Imatinib after Failure of Interferon-Alfa Is Equivalent to That of Patients Achieving Major Molecular Responses to Imatinib as Primary Therapy.

Abnormally Small BCR-ABL Transcripts in CML Patients before and during Imatinib Treatment.

Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd-Chiari Syndrome.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only